Novel neuroprotective agents for schizophrenia: Neurosteroids, memantine, bexarotene and l-theanine

New Hope for Mental Disturbances

Volumn , Issue , 2009, Pages 119-120

  Ritsner, Michael S ^a,b  

^a SHA'AR MENASHE MENTAL HEALTH CENTER   (Israel)

^b TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Bexarotene; Memantine; Neuroprotective agents; Neurosteroids; Schizophrenia; Theanine

Indexed keywords

EID: 84919658249     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (186)

1. Akhondzadeh, S., Stone, T.W. Potentiation of muscimol-induced long-term depression by benzodiazepines and prevention or reversal by pregnenolone sulfate. Pharmacol. Res., 1998, 38, 441-448.
2. Akwa Y, Baulieu EE. Dehydroepiandrosterone sulfate and dehydroepiandrosterone: neuroactive neurosteroids. Current Opinion in Endocrinology and Diabetes, 2000, 7,160-167.
3. Arinami T, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Human Molecular Genetics, 1997, 6, 577-582.
4. Banerjee SP, Zuck LG, Yablonsky-Alter E, Lidsky TI. Glutamate agonist activity: implications for antipsychotic drug action and schizophrenia. Neuroreport, 1995, 6, 2500-2504.
5. Bastianetto S, Ramassamy C, Poirier J, Quirion R. Dehydroepiandrosterone (DHEA) protects hippocampal cells from oxidative stress-induced damage. Brain Res. Mol. Brain Res., 1999, 20, 66, 35-41.
6. Baulieu EE, Robel P. Neurosteroids: a new brain function? Journal of Steroid Biochemistry and Molecular Biology, 1990, 37, 395-403.
7. Baulieu EE, Robel P. Dehydroepiandrosterone and dehydroepiandrosterone sulfate as neuroactive neurosteroids. Journal of Endocrinology, 1996, 50, 221-239.
8. Baulieu, E.E. Neurosteroids: of the nervous system, by the nervous system, for the nervous system. Recent Prog. in Hormone Res., 1997, 52, 1-32.
9. Baulieu, E.E. Neurosteroids: a novel function of the brain. Psychoneuroendocrinology, 1998, 23, 963-987.
10. Belelli D, Lambert JJ. Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat. Rev. Neurosci., 2005,6,565-75.
11. Akhondzadeh, S., Stone, T.W. Potentiation of muscimol-induced long-term depression by benzodiazepines and prevention or reversal by pregnenolone sulfate. Pharmacol. Res., 1998, 38, 441-448.
12. Akwa Y, Baulieu EE. Dehydroepiandrosterone sulfate and dehydroepiandrosterone: neuroactive neurosteroids. Current Opinion in Endocrinology and Diabetes, 2000, 7,160-167.
13. Arinami T, Gao M, Hamaguchi H, Toru M. A functional polymorphism in the promoter region of the dopamine D2 receptor gene is associated with schizophrenia. Human Molecular Genetics, 1997, 6, 577-582.
14. Banerjee SP, Zuck LG, Yablonsky-Alter E, Lidsky TI. Glutamate agonist activity: implications for antipsychotic drug action and schizophrenia. Neuroreport, 1995, 6, 2500-2504.
15. Bastianetto S, Ramassamy C, Poirier J, Quirion R. Dehydroepiandrosterone (DHEA) protects hippocampal cells from oxidative stress-induced damage. Brain Res. Mol. Brain Res., 1999, 20, 66, 35-41.
16. Baulieu EE, Robel P. Neurosteroids: a new brain function? Journal of Steroid Biochemistry and Molecular Biology, 1990, 37, 395-403.
17. Baulieu EE, Robel P. Dehydroepiandrosterone and dehydroepiandrosterone sulfate as neuroactive neurosteroids. Journal of Endocrinology, 1996, 50, 221-239.
18. Baulieu, E.E. Neurosteroids: of the nervous system, by the nervous system, for the nervous system. Recent Prog. in Hormone Res., 1997, 52, 1-32.
19. Baulieu, E.E. Neurosteroids: a novel function of the brain. Psychoneuroendocrinology, 1998, 23, 963-987.
20. Belelli D, Lambert JJ. Neurosteroids: endogenous regulators of the GABA(A) receptor. Nat. Rev. Neurosci., 2005,6,565-75.
21. Chambon P: The retinoid signaling pathway: Molecular and genetic analyses. Semin. Cell Biol., 1994, 5, 115-125.
22. Danysz W, Parsons CG. The NMDA receptor antagonist memantine as a symptomatological and neuroprotective treatment for Alzheimer's disease: preclinical evidence. Int. J. Geriatr. Psychiatry, 2003; 18 (suppl 1), 23-32.
23. Debonnel G, Bergeron R, de Montigny C. Potentiation by dehydroepiandrosterone of the neuronal response to N-methyl-D-aspartate in the CA3 region of the rat dorsal hippocampus: an effect mediated via sigma receptors. J. Endocrinol., 1996, 150 (Suppl), 33-42.
24. Diamond DM, Branch BJ, Fleshner M.The neurosteroids dehydroepiandrosterone sulfate (DHEAS) enhances hippocampal primed burst, but not long-term potentiation. Neuroscience Lett., 1996, 202, 204-208.
25. Dy, Grace K.; Adjei, Alex A. Novel Targets for Lung Cancer Therapy: Part I. Journal of Clinical Oncology, 2002, 20, 2881-2894.
26. Ehrenreich H, Siren AL. Neuroprotection--what does it mean?--What means do we have? Eur. Arch Psychiatry Clin. Neurosci., 2001, 251, 149-151.
27. Ehrenreich H, Aust C, Krampe H, Jahn H, Jacob S, Herrmann M, Siren AL. Erythropoietin: novel approaches to neuroprotection in human brain disease. Metab. Brain Dis., 2004, 19, 195-206.
28. Egashira N, Hayakawa K, Mishima K, Kimura H, Iwasaki K, Fujiwara M. Neuroprotective effect of gamma-glutamylethylamide (theanine) on cerebral infarction in mice. Neurosci. Lett., 2004, 363, 58-61.
29. Ekborg-Ott KH, Taylor A, Armstrong DW. Varietal differences in the total and enantiomeric composition of theanine in tea. J. Agric. Food Chem., 1997, 45, 353-363.
30. Esteva, Francisco J.; Glaspy, John; Baidas, Said; Laufman, Leslie; Hutchins, Laura; Dickler, Maura; Tripathy, Debu; Cohen, Roger; DeMichele, Angela; Yocum, Richard C.; Osborne, C. Kent; Hayes, Daniel F.; Hortobagyi, Gabriel N.; Winer, Eric; Demetri, George D. Multicenter Phase II Study of Oral Bexarotene for Patients With Metastatic Breast Cancer. Journal of Clinical Oncology, 2003, 21, 999-1006.
31. Fletcher EJ, MacDonald JF: Haloperidol interacts with the strychnine-insensitive glycine site at the NMDA receptor in cultured mouse hippocampal neurones. Eur. J. Pharmacol., 1993, 235, 291-295.
32. Flood, J.F., Morley, J.E., Roberts, E. Memory-enhancing effects in male mice of Pregnenolone and steroids metabolically derived from it. Proc. Natl. Acad. Sci., 1992, 89, 1567-1571.
33. Flood, J.F., Morley, J.E., Roberts, E. Pregnenolone sulfate enhances post-training memory processes when injected in very low doses into limbic system structures: the amygdala is by far the most sensitive. Proc. Natl. Acad. Sci. USA, 1995, 92, 10806-10810.
34. Friess E.,T. Schiffelholz,T. Steckler and A. Steiger. Dehydroepiandrosterone - a neurosteroids. European Journal of Clinical Investigation, 2000, 30 (Suppl. 3), 46-50.
35. Gambi F, De Berardis D, Sepede G, Quartesan R, Calcagni E, Salerno RM, Conti CM, Ferro FM. Cannabinoid receptors and their relationships with neuropsychiatric disorders. Int. J. Immunopathol. Pharmacol., 2005, 18, 15-19.
36. Gasior, M., Carter, R.B., Witkin, J.M. Neuroactive steroids: potential therapeutic use in neurological and psychiatric disorders. Trends Pharmacol. Sci, 1999, 20, 107-112.
37. George, M.S., Guidotti, A., Rubinow, D., Pan, P., Mikalauskas, K., Post, R.M. CSF neuroactive steroids in affective disorders: pregnenolone, progesterone and DBI. Biol. Psychiatry, 1994, 35, 775-780.
38. Goff, DC, Coyle, JT. The Emerging Role of Glutamate in the Pathophysiology and Treatment of Schizophrenia. Am. J. Psychiatry, 2001,158,1367-1377.
39. Goodyer IM, Park RJ, Netherton CM, Herbert J. Possible role of cortisol and dehydroepiandrosterone in human development and psychopathology. British Journal of Psychiatry, 2001,179, 243-249.
40. Gorgun G, Foss F. Immunomodulatory effects of RXR rexinoids: modulation of high-affinity IL-2R expression enhances susceptibility to denileukin diftitox. Blood, 2002,100, 1399-1403.
41. Goodman, A.B. Chromosomal locations and modes of action of genes of the retinoid (vitamin A) system support their involvement in the etiology of schizophrenia. American Journal of Medical Genetics, 1995, 60, 335-348.
42. Goodman, AB: Congenital anomalies of schizophrenic probands may indicate a retinoid pathology. Schizophrenia Research, 1996, 19, 163-170.
43. Goodman,AB.Three independent lines of evidence suggest retinoids as causal to schizophrenia. Proc. Natl. Acad. Sci. USA, 1998, 95, 7240-44.
44. Guazzo EP, Kirkpatrick PJ, Goodyer IM, Shiers HM, Herbert J. Cortisol, dehydroepiandrosterone (DHEA), and DHEA sulfate in the cerebrospinal fluid of man: relation to blood levels and the effects of age. J. Clin. Endocrinol. Metab., 1996, 81, 3951-3960.
45. Gursoy E, Cardounel A, Kalimi M. Pregnenolone protects mouse hippocampal (HT-22) cells against glutamate and amyloid beta protein toxicity. Neurochem. Res., 2001, 26, 15-21.
46. Hashimoto T, Bergen SE, Nguyen QL, et al. Relationship of brain-derived neurotrophic factor and its receptor TrkB to altered inhibitory prefrontal circuitry in schizophrenia. J. Neurosci., 2005, 25, 372-383.
47. Heresco-Levy U, Javitt D, Ermilov M, Mordel C, Silipo G, Lichenstein M: Efficacy of highdose glycine in the treatment of enduring negative symptoms of schizophrenia. Arch Gen. Psychiatry, 1999, 56, 29-36.
48. Heydari, B. and Le Melledo, J.M. Low pregnenolone sulphate plasma concentrations in patients with generalized social phobia. Psychol. Med., 2002, 32, 929-933.
49. Hong WK, Lippman SM, Itri LM, et al: Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl. J. Med, 1990, 323, 795-801.
50. Hu Y, Cardounel A, Gursoy E, Anderson P, Kalimi M. Anti-stress effects of dehydroepiandrosterone: protection of rats against repeated immobilization stressinduced weight loss, glucocorticoid receptor production, and lipid peroxidation. Biochem. Pharmacol., 2000, 59, 753-762.
51. Hurst RE. Bexarotene ligand pharmaceuticals. Curr. Opin. Investig. Drugs, 2000, 1, 514-523.
52. Ito K, Nagato Y, Aoi N, et al. Effects of L-theanine on the release of alpha-brain waves in human volunteers. Nippon Nogeikagaku Kaishi, 1998, 72, 153-157.
53. Jann MW. Implications for atypical antipsychotics in the treatment of schizophrenia: neurocognition effects and a neuroprotective hypothesis. Pharmacotherapy, 2004, 24,1759-1783.
54. Jarskog LF, Selinger ES, Lieberman JA, Gilmore JH. Apoptotic proteins in the temporal cortex in schizophrenia: high Bax/Bcl-2 ratio without caspase-3 activation. Am. J. Psychiatry, 2004, 161, 109-115.
55. Javitt DC, Zylberman I, Zukin SR, Heresco-Levy U, Lindenmayer JP. Amelioration of negative symptoms in schizophrenia by glycine. Am. J. Psychiatry, 1994, 151,1234-1236.
56. Juneja LR, Chu DC, Okubo T, Nagato Y, Yokogoshi H. L-theanine-a unique amino acid of green tea and its relaxation effect in humans. Trends Food Sci. Technol.,1999, 10,199-204.
57. Kakuda T. Neuroprotective effects of the green tea components theanine and catechins. Biol. Pharm. Bull., 2002, 25, 1513-1518.
58. Kakuda T, Matsuura T, Sagesaka Y, Kawasaki T. Product and method for inhibiting caffeine stimulation with theanine. US Patent 5,501,866; 1996.
59. Kakuda T, Nozawa A, Unno T, Okamura N, Okai O. Inhibiting effects of theanine on caffeine stimulation evaluated by EEG in the rat. Biosci. Biotechnol. Biochem., 2000, 64, 287-293.
60. Kakuda T, Nozawa A, Sugimoto A, Niino H. Inhibition by theanine of binding of [3H] AMPA, [3H] kainate, and [3H]MDL 105,519 to glutamate receptors. Biosci. Biotechnol. Biochem., 2002, 66, 2683-2686.
61. Kamath AB, Wang L, Das H, Li L, Reinhold VN, et al. Antigens in tea-beverage prime human ?d T cells in vitro and in vivo for memory and nonmemory antibacterial cytokine responses. Proc. Natl. Acad. Sci. USA, 2003,100, 6009-6014.
62. Karishma KK, Herbert J. Dehydroepiandrosterone (DHEA) stimulates neurogenesis in the hippocampus of the rat, promotes survival of newly formed neurons and prevents corticosterone-induced suppression. Eur. J. Neurosci., 2002, 16, 445-453.
63. Kent JM, Mathew SJ, Gorman JM. Molecular targets in the treatment of anxiety. Biol. Psychiatry, 2002, 52,1008-1030.
64. Khuri FR, Rigas JR, Figlin RA, Gralla RJ, Shin DM, Munden R, Fox N, Huyghe MR Multiinstitutional phase I/II trial of oral bexarotene in combination with cisplatin and vinorelbine in previously untreated patients with advanced non-small-cell lung cancer. J. Clin. Oncol., 2001, 19, 2626-2637.
65. Kimonides VG, Khatibi NH, Svendsen CN, Sofroniew MV, Herbert J. Dehydroepiandrosterone (DHEA) and DHEA-sulfate (DHEAS) protect hippocampal neurons against excitatory amino acid-induced neurotoxicity. Proc. Natl. Acad. Sci. USA, 1998, 95, 1852-1857.
66. Kimonides VG, Spillantini MG, Sofroniew MV, Fawcett JW, Herbert J. Dehydroepiandrosterone antagonizes the neurotoxic effects of corticosterone and translocation of stress-activated protein kinase 3 in hippocampal primary cultures. Neuroscience, 1999, 89, 429-436.
67. Kimura R, Murata T. Influence of alkylamides of glutamic acid and related compounds on the central nervous system. I. Central depressant effect of theanine. Chem. Pharm. Bull. (Tokyo), 1971,19, 1257-1261.
68. Kimura R, Murata T. Effect of theanine on norepinephrine and serotonin levels in rat brain. Chem. Pharm. Bull. (Tokyo), 1986, 34, 3053-3057.
69. Kimura R, Murata T. Influence of alkylamides of glutamic acid and related compounds on the central nervous system. I. Central depressant effect of theanine. Chem. Pharm. Bull. (Tokyo), 1971, 19, 1257-12561.
70. Kitaoka S, Hayashi H, Yokogoshi H, Suzuki Y. Transmural potential changes associated with the in vitro absorption of theanine in the guinea pig intestine. Biosci. Biotechnol. Biochem., 1996, 60, 1768-17671.
71. Kito M, Kokura H, Izaki J, Sasaoka K. Theanine, a precursor of the phloroglucinol nucleus of catechins in the tea plants. Phytochemistry, 1968, 7, 599-603.
72. Knoll JL, Garver DL, Ramberg JE, Kingsbury SJ, Croissant D, McDermott B. Heterogeneity of the psychoses: is there a neurodegenerative psychosis? Schizophr. Bull., 1998, 24, 365-379.
73. Kobayashi K, Nagato Y, Aoi N, Juneja LR, Kim M, et al. Effects of L-theanine on the release of a-brain waves in human volunteers. Nippon Nogeikagaku Kaishi, 1998, 72, 153-157.
74. Krebs M, Leopold K, Hinzpeter A, Schaefer M. Neuroprotective agents in schizophrenia and affective disorders. Expert Opin. Pharmacother., 2006, 7, 837-848.
75. Krezel W, Ghyselinck N, Samad TA, Dupe V, Kastner P, Borrelli E, Chambon P Impaired locomotion and dopamine signaling in retinoid receptor mutant mice. Science, 1998, 279, 863-867.
76. Kurata K, Takebayashi M, Morinobu S, Yamawaki S. Beta-estradiol, dehydroepiandrosterone, and dehydroepiandrosterone sulfate protect against N-methyl-D-aspartateinduced neurotoxicity in rat hippocampal neurons by different mechanisms. J Pharmacol. Exp. Ther., 2004, 311, 237-245.
77. Lang UE, Jockers-Scherubl MC, Hellweg R. State of the art of the neurotrophin hypothesis in psychiatric disorders: implications and limitations. J. Neural. Transm., 2004, 111, 387-411.
78. Lapchak PA, Araujo DM. Preclinical development of neurosteroids as neuroprotective agents for the treatment of neurodegenerative diseases. Int. Rev. Neurobiol., 2001, 46, 379-397.
79. Le Goascogne, C., Robel, P., Gouezou, M., Sananes, N., Baulieu, E-E. and Waterman, M. Neurosteroids: cytochrome P-450scc in rat brain. Science, 1987, 237, 1212-1215.
80. Leid M, Kastner P, Chambon P: Multiplicity generates diversity in the retinoic acid signaling pathways. Trends Biochem. Sci, 1992, 17, 427-433.
81. Lewis DA, Levitt P. Schizophrenia as a disorder of neurodevelopment. Annu. Rev. Neurosci., 2002, 25, 409-432.
82. Lhullier FL, Nicolaidis R, Riera NG, Cipriani F, Junqueira D, Dahm KC, Brusque AM, Souza DO. Dehydroepiandrosterone increases synaptosomal glutamate release and improves the performance in inhibitory avoidance task. Pharmacol. Biochem. Behav., 2004, 77, 601-606.
83. Lidsky TI, Yablonsky-Alter E, Zuck LG, Banerjee SP: Antipsychotic drug effects on glutamatergic activity. Brain Res., 1997, 764, 46-52.
84. Lu K, Gray MA, Oliver C, Liley DT, Harrison BJ, Bartholomeusz CF, Phan KL,Nathan PJ.The acute effects of L-theanine in comparison with alprazolam on anticipatory nxiety in humans. Hum. Psychopharmacol., 2004, 19, 457-465.
85. McGavack, T.H., Chevalley, J., Weissberg, J. The use of delta-5-pregnenolone in various clinical disorders. J. Clin. Endocrinol., 1951, 11, 559-577.
86. McCoy L, Richfield EK: Chronic antipsychotic treatment alters glycine-stimulated NMDA receptor binding in rat brain. Neurosci. Lett., 1996, 213, 137-141.
87. Mahadik SP, Evans D, Lal H. Oxidative stress and role of antioxidant and omega-3 essential fatty acid supplementation in schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2001, 25, 463-493.
88. Manji HK, Moore GJ, Chen G. Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol. Psychiatry, 1999, 46, 929-940.
89. Majewska MD, Demirgoren S, Spivak CE, London ED. The neurosteroid dehydroepiandrosterone sulfate is an antagonist of the GABA-A receptor. Brain Res., 1990, 526, 143-146.
90. Majewska MD. Neurosteroids: endogenous bimodal modulators of the GABAA receptor. Mechanism of action and physiological significance. Prog Neurobiol., 1992, 38, 379-395.
91. Majewska MD. Neuronal actions of dehydroepiandrosterone. Possible roles in brain development, aging, memory, and affect. Ann. N Y Acad. Sci., 1995, 774,111-120.
92. Mao X, Barger SW. Neuroprotection by dehydroepiandrosterone-sulfate: role of an NFkappaB-like factor. Neuroreport., 1998, 9, 759-763.
93. Martin S, Bradley J, Cotter T: HL-60 cells induced to differentiate towards neutrophils subsequently die via apoptosis. Clin. Exp. Immunol., 1990, 79, 448-453.
94. Marx CE, Stevens RD, Shampine LJ, Uzunova V, Trost WT, Butterfield MI, Massing MW, Hamer RM, Morrow AL, Lieberman JA. Neuroactive steroids are altered in schizophrenia and bipolar disorder: relevance to pathophysiology and therapeutics. Neuropsychopharmacology, 2006, 31, 1249-1263.
95. Mason R. 200 mg of Zen; L-theanine boosts alpha waves, promotes alert relaxation. Alternative and Complementary Therapies, 2001, 7, 91-95.
96. Mayo, W., Le Moal, M. and Abrous, D.N. Pregnenolone sulfate and aging of cognitive functions: behavioral, neurochemical, and morphological investigations. Hormonal Behav., 2001, 40, 215-217.
97. McCaffery P, Drager DC. High levels of a retinoic acid-generating dehydrogenase in the meso telencephalic dopamine system. Proceedings of the National Academy of Sciences (USA), 1994, 91, 7772-7776.
98. McGlashan TH, Hoffman RE. Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Arch Gen. Psychiatry, 2000, 57, 637-648.
99. Meador-Woodruff JH, Healy DJ: Glutamate receptor expression in schizophrenic brain. Brain Res. Brain Res. Rev., 2000, 31, 288-294.
100. Meieran SE, Reus VI, Webster R, Shafton R, Wolkowitz OM. Chronic pregnenolone effects in normal humans: attenuation of benzodiazepine-induced sedation. Psychoneuroendocrinology, 2004, 29, 486-500.
101. Melchior, C.L., Ritzmann, R.F. Pregnenolone and pregnenolone sulfate, alone and with ethanol, in mice on the plus-maze. Pharmacol. Biochem. Behav., 1994, 48, 893-897.
102. Middleton FA, Mirnics K, Pierri JN, Lewis DA, Levitt P. Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J. Neurosci., 2002, 22, 2718-2729.
103. Migues PV, Johnston AN, Rose SP. Dehydroepiandosterone and its sulphate enhance memory retention in day-old chicks. Neuroscience, 2002, 109, 243-251.
104. Miguel-Hidalgo JJ, Alvarez XA, Cacabelos R, Quack G. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid(1-40). Brain Res., 2002, 958, 210-221.
105. Millan MJ. The neurobiology and control of anxious states. Prog. Neurobiol., 2003, 70, 83-244.
106. Misner DL, Jacobs S, Shimizu Y, de Urquiza AM, Solomin L, Perlmann T, De Luca LM, Stevens CF, Evans RM. Vitamin A deprivation results in reversible loss of hippocampal long-term synaptic plasticity. Proc. Natl. Acad. Sci. USA, 2001, 98, 11714-11719.
107. Moises HW, Zoega T, Gottesman II. The glial growth factors deficiency and synaptic destabilization hypothesis of schizophrenia. BMC Psychiatry, 2002, 3, 2:8.
108. Murray RM. Neurodevelopmental schizophrenia: the rediscovery of dementia praecox. Br. J. Psychiatry Suppl., 1994, 25, 6-12.
109. Nachshoni T, Ebert T, Abramovitch Y, Assael-Amir M, Kotler M, Maayan R, Weizman A, Strous RD.Improvement of extrapyramidal symptoms following dehydroepiandrosterone (DHEA) administration in antipsychotic treated schizophrenia patients: a randomized, double-blind placebo controlled trial. Schizophr. Res., 2005, 79, 251-256.
110. Nafziger AN, Bowlin SJ, Jenkins PL, et al: Longitudinal changes in dehydroepiandrosterone concentrations in men and women. J. Lab. Clin. Med., 1998, 131, 316-323.
111. Nagasawa K, Aoki H, Yasuda E, Nagai K, Shimohama S, Fujimoto S. Possible involvement of group I mGluRs in neuroprotective effect of theanine. Biochem. Biophys. Res. Commun., 2004, 320, 116-122.
112. Neeman G, Blanaru M, Bloch B, Kremer I, Ermilov M, Javitt DC, Heresco-Levy U. Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type. Am. J. Psychiatry, 2005, 162,1738-1740.
113. Nozawa A, Umezawa K, Kobayashi K, Kawahara M, Muramoto K, et al. Theanine, a major flavorous amino acid in green tea leaves, inhibits glutamate-induced neurotoxicity on cultured rat cerebral cortical neurons. Soc. Neurosci. Abstr., 1998, 24(382.6).
114. Okubo T, Ozeki M, Inden T, Juneja LR, Hisanabe M, et al. Compositions for regulating desire for smoking. US Patent Application, 2003/003130; Jan. 2, 2003.
115. Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F. Efficacy and safety of memantine in patients with mild-moderate vascular dementia: a randomized, placebo controlled trial (MMM 300). Stroke, 2002, 33,1834-1839.
116. Oridate N, Lotan D, Xu XC, et al: Differential induction of apoptosis by all-trans-retinoic acid and N-(4-hydroxyphenyl)retinamide in human head and neck squamous cell carcinoma cell lines. Clin. Cancer Res., 1996, 2, 855-863.
117. Ozeki M, Yao H, Okubo T, Juneja LR. Compositions for promoting sleep. US Patent Application 2002/0188025, 2002.
118. Querfeld C, Nagelli LV, Rosen ST, Kuzel TM, Guitart J. Bexarotene in the treatment of cutaneous T-cell lymphoma. Expert Opin. Pharmacother., 2006, 7, 907-915.
119. Piketty C, Jayle D, Leplege A, Castiel P, Ecosse E, Gonzalez-Canali G, Sabatier B, Boulle N, Debuire B, Le Bouc Y, Baulieu EE, Kazatchkine MD. Double-blind placebo-controlled trial of oral dehydroepiandrosterone in patients with advanced HIV disease. Clin. Endocrinol. (Oxf)., 2001, 55, 325-330.
120. Pincus, G., Hoagland, H.Effects of administered pregnenolone on fatiguing psychomotor performance. J. Aviation Med., 1944, 15, 98-115.
121. Pincus, G., Hoagland, H. Effects on industrial production of the administration of Pregnenolone to factory workers, I. Psychosom. Med., 1945, 7, 342-346.
122. Pisu MG, Serra M. Neurosteroids and neuroactive drugs in mental disorders. Life Sci., 2004, 74, 3181-3197.
123. Potyk, D. Treatments for Alzheimer disease. South Med. J. 2005 Jun;98(6):628-35.
124. Racchi M, Balduzzi C, Corsini E. Dehydroepiandrosterone (DHEA) and the aging brain: flipping a coin in the "fountain of youth". CNS Drug Rev., 2003, 9, 21-40.
125. Rapoport JL, Addington AM, Frangou S, Psych MR. The neurodevelopmental model of schizophrenia: update 2005. Mol. Psychiatry, 2005, 10, 434-449.
126. Rasmusson AM, Vythilingam M, Morgan CA 3rd. The neuroendocrinology of posttraumatic stress disorder: new directions. CNS Spectr., 2003, 8, 651-656, 665-667.
127. Reddy, D.S., Kaur, G., Kulkarni, S.K. Sigma (sigma1) receptor mediated anti-depressant-like effects of neurosteroids in the Porsolt forced swim test. Neuroreport., 1998, 9, 3069-3073.
128. Reisberg B, Doody R, Stoffler A, et al. Memantine in moderate-tosevere Alzheimer disease. NEJM, 2003, 348, 1333-1341.
129. Rigas JR, Maurer LH, Meyer LP, Hammond SM, Crisp MR, Parker BA, Truglia JA. Targretin, a selective retinoid X receptor ligand (LGD1069), vinorelbine and cisplatin for the treatment of non-small cell lung cancer (NSCLC): a phase I/II trial. Proc. Annu. Meet Am. Soc. Clin. Oncol., 1997,16, A1724.
130. Ritsner MS, Maayan R, Gibel A, Weizman A. Low serum pregnenolone levels are associated with trait-anxiety, but not with clinical symptomatology among chronic treated patients with schizophrenia. European Neuropsychopharmacology, 2006a, in press.
131. Ritsner, MS, Gibel, A., Ratner, Y., Tsinovoy, G., Strous, D. Improvement of sustained attention, visual and movement skills, but not clinical symptomatology, following dehydroepiandrosterone augmentation in schizophrenia: a randomized double-blind, placebo-controlled, crossover trial. Int. Clin. Psychopharmacol., 2006b (in press).
132. Roberts, E., Fitten, L.J. Serum steroid levels in two old men with Alzheimer's disease (AD) before and after oral administration of dehydroepiandrosterone (DHEA). Pregnenolone synthesis may be ratelimiting in aging. In: Kalimi, M., Regelson, W. (Eds.), The Biological Role of Dehydroepiandrosterone (DHEA). de Gruyter, Berlin, 1990, 43-63.
133. Rogawski MA, Wenk GL. The neuropharmacological basis for the use of memantine in the treatment of Alzheimer's disease. CNS Drug Rev., 2003, 9, 275-308.
134. Rogawski MA, What is the rationale for new treatment strategies in Alzheimer's disease? CNS Spectr., 2004, 9(7 Suppl 5), 6-12.
135. Roozendaal B, McGaugh JL.Amygdaloid nuclei lesions differentially affect glucocorticoidinduced memory enhancement in an inhibitory avoidance task. Neurobiol. Learn Mem., 1996, 65, 1-8.
136. Rupprecht, R. The neuropsychopharmacological potential of neuroactive steroids. J. Psychiatr. Res., 1997, 31, 297-314.
137. Sadzuka Y, Sugiyama T, Miyagishima A, Nozawa Y, Hirota S. The effects of theanine, as a novel biochemical modulator, on the antitumor activity of adriamycin. Cancer Lett., 1996, 105, 203-209.
138. Sadzuka Y, Sugiyama T, Sonobe T. Improvement of idarubicin induced antitumor activity and bone marrow suppression by theanine, a component of tea. Cancer Lett., 2000, 158,119-124.
139. Sadzuka Y, Sugiyama T, Suzuki T, Sonobe T. Enhancement of the activity of doxorubicin by inhibition of glutamate transporter. Toxicol. Lett., 2001, 123,159-167.
140. Sadzuka Y, Yamashita Y, Kishimoto S, Fukushima S, Takeuchi Y, et al. Glutamate transporter mediated increase of antitumor activity by theanine, an amino acid in green tea [in Japanese]. Yakugaku Zasshi., 2002, 122, 995-999.
141. Sadzuka Y, Sugiyama T, Nagamine M, Umegaki K, Sonobe T. Efficacy of theanine is connected with theanine metabolism by any enzyme, not only drug metabolizing enzymes. Food Chem. Toxicol., 2006, 44, 286-292.
142. Sakato Y. The chemical constituents of tea: III. A new amide theanine. Nippon Nogeikagaku Kaishi, 1949, 23, 262-267.
143. Samad T A, Krezel W, Chambron P, Borrelli E. Regulation of dopaminergic pathways by retinoids: activation of the D2 receptor promoter by members of the retinoic acid receptor-retinoid X receptor family. Proceedings of the National Academy of Sciences (USA), 1997, 94, 14349-14354.
144. Satre MA, Ugen KE, Kochhar DM. Developmental changes in endogenous retinoids during pregnancy and embryogenesis in the mouse. Biology of Reproduction, 1992, 46, 802-810.
145. Schmidt WJ, Kretschmer BD. Behavioural pharmacology of glutamate receptors in the basal ganglia. Neurosci. Biobehav. Rev., 1997, 21, 381-392.
146. Schmidt PJ, Daly RC, Bloch M, Smith MJ, Danaceau MA, St Clair LS, Murphy JH, Haq N, Rubinow DR. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Arch Gen. Psychiatry, 2005, 62, 154-162.
147. Shenton ME, Dickey CC, Frumin M, McCarley RW. A review of MRI findings in schizophrenia. Schizophr. Res., 2001, 49, 1-52.
148. Sherman SI. Etiology, diagnosis, and treatment recommendations for central hypothyroidism associated with bexarotene therapy for cutaneous T-cell lymphoma. Clin. Lymphoma, 2003, 3, 249-252.
149. Semeniuk, T., Jhangri, G., Le Melledo, J. Neuroactive steroid levels in patients with generalized anxiety disorder. J. Neuropsychiatry Clin. Neurosci., 2001, 13, 396-398.
150. Shalita, A.R. Mucocutaneous and systemic toxicity of retinoids: monitoring and management. Dermatologica, 1987, 1, 151-157.
151. Sleeper, RB. Antipsychotic dose-sparing effect with addition of memantine. Ann. Pharmacother., 2005, 39, 1573-1576.
152. Smit JV, De Jong EM, Van De Kerkhof PC. Effects of Oral Bexarotene (Targretin) on the Minimal Erythema Dose for Broadspectrum UVB Light. Skin Pharmacol. Appl. Skin Physiol., 2003, 16, 237-241.
153. Sporn M, Roberts A: Role of retinoids in differentiation and carcinogenesis. J. Natl. Cancer Inst., 1984, 73, 1381-1387.
154. Stark AK, Uylings HB, Sanz-Arigita E, Pakkenberg B. Glial cell loss in the anterior cingulate cortex, a subregion of the prefrontal cortex, in subjects with schizophrenia. Am. J. Psychiatry, 2004, 161, 882-888.
155. Stoffel-Wagner B. Neurosteroid metabolism in the human brain. Eur. J. Endocrinol., 2001, 145, 669-679.
156. Stoffel-Wagner, B. Neurosteroid biosynthesis in the human brain and its clinical implications. Ann. N. Y. Acad. Sci., 2003, 1007, 64-78.
157. Strous RD, Maayan R, Lapidus R, Stryjer R, Lustig M, Kotler M, Weizman A. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen. Psychiatry, 2003, 60, 133-141.
158. Sugiyama T, Sadzuka Y. Theanine, a specific glutamate derivative in green tea, reduces the adverse reactions of doxorubicin by changing the glutathione level. Cancer Lett., 2004, 212, 177-184.
159. Tagawa, N., Tamanaka, J., Fujinami, A., Kobayashi, Y., Takano, T., Fukata, S., Kuma, K., Tada, H. and Amino, N. Serum dehydroepiandrosterone, dehydropiandrosterone sulfate, and pregnonolone sulfate concentrations in patients with hyperthyroidism and hypothyroidism. Clin. Chem., 2000, 46, 523-528.
160. Takahashi H, Nakajima A, Sekihara H.Dehydroepiandrosterone (DHEA) and its sulfate (DHEAS) inhibit the apoptosis in human peripheral blood lymphocytes. J. Steroid Biochem. Mol. Biol., 2004, 88, 261-264.
161. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, for the Memantine Study Group. Memantine treatment in patients with moderate to severe Alzheimer's disease already receiving donepezil: a randomized controlled trial. JAMA, 2004, 291, 317-324.
162. Terashima T, Takido J, Yokogoshi H. Time-dependent changes of amino acids in the serum, liver, brain and urine of rats administered with theanine. Biosci. Biotechnol. Biochem., 1999, 63, 615-618.
163. Thomas, C. Memantine and Catatonic Schizophrenia. Am. J. Psychiatry, 2005, 162, 626.
164. Tsuge H, Sano S, Hayakawa T, Kakuda T, Unno T. Theanine, ?-glutamylethylamide, is metabolized by renal phosphate-independent glutaminase. Biochim. Biophys. Acta, 2003, 1620, 47-53.
165. Tsutsui K, Matsunaga M, Miyabara H, Ukena K. Neurosteroid biosynthesis in the quail brain: a review. J. Exp. Zoolog. A Comp. Exp. Biol., 2006, 305, 733-742.
166. Ueda T, Nagato Y, Tanaka Y, Okubo T, Kobayashi K, et al. Composition comprising theanine. US Patent 6, 589, 566; July 8, 2003.
167. Unno T, Suzuki Y, Kakuda T, Hayakawa T, Tsuge H. Metabolism of theanine, ?- glutamylethylamide, in rats. J. Agric. Food Chem., 1999, 47,1593-1596.
168. Yokogoshi H, Kato Y, Sagesaka YM, Takihara-Matsuura T, Kakuda T, et al. Reduction effect of theanine on blood pressure and brain 5-hydroxyindoles in spontaneously hypertensive rats. Biosci. Biotechnol. Biochem., 1995, 59, 615-618.
169. Yokozawa T, Dong E. Influence of green tea and its three major components upon lowdensity lipoprotein oxidation. Exp. Toxicol. Pathol., 1997, 49, 329-335.
170. Yokogoshi H, Kobayashi M, Mochizuki M, Terashima T. Effect of theanine, rglutamylethylamide, on brain monoamines and striatal dopamine release in conscious rats. Neurochem. Res., 1998a, 3, 667-673.
171. Yokogoshi H, Mochizuki M, Saitoh K. Theanine-induced reduction of brain serotonin concentration in rats. Biosci. Biotech. Biochem., 1998b, 62, 816-817.
172. Yokogoshi H, Kobayashi M. Hypotensive effect of gamma-glutamylmethylamide in spontaneously hypertensive rats. Life Sci., 1998c, 62, 1065-1068.
173. van Vollenhoven RF. Dehydroepiandrosterone for the treatment of systemic lupus erythematosus. Expert Opin. Pharmacother., 2002, 3, 23-31.
174. Veiga S, Garcia-Segura LM, Azcoitia I. Neuroprotection by the steroids pregnenolone and dehydroepiandrosterone is mediated by the enzyme aromatase. J. Neurobiol., 2003, 56, 398-406.
175. Wagner E, Luo T, Drager UC. Retinoic acid synthesis in the postnatal mouse brain marks distinct developmental stages and functional systems. Cereb. Cortex., 2002,12, 1244-1253.
176. Wen S, Dong K, Onolfo JP, Vincens M. Treatment with dehydroepiandrosterone sulfate increases NMDA receptors in hippocampus and cortex. Eur. J. Pharmacol., 2001, 430, 373-374.
177. Wenk GL, Danysz W, Mobley SL. MK-801, memantine and amantadine show neuroprotective activity in the nucleus basalis magnocellularis. Eur. J. Pharmacol. Environ. Toxicol., 1995, 293, 267-270.
178. Wenk GL. Neuropathologic changes in Alzheimer's disease: potential targets for treatment. J. Clin. Psychiatry, 2006, 67 (Suppl 3), 3-7.
179. Widstrom RL, Dillon JS. Is there a receptor for dehydroepiandrosterone or dehydroepiandrosterone sulfate? Semin. Reprod. Med., 2004, 22, 289-298.
180. Winblad B, Poritis N. Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int. J. Geriatr. Pysch., 1999, 14, 135-146.
181. Wolf OT, Kirschbaum C. Actions of dehydroepiandrosterone and its sulfate in the central nervous system:effects on cognition and emotion in animals and humans. Brain Res. Brain Res. Rev., 1999, 30, 264-288.
182. Wolkowitz OM, Reus VI, Roberts E, Manfredi F, Chan T, Raum WJ, Ormiston S, Johnson R, Canick J, Brizendine L, Weingartner H. Dehydroepiandrosterone (DHEA) treatment of depression. Biol. Psychiatry, 1997, 41, 311-318.
183. Wolkowitz OM, Reus VI, Keebler A, Nelson N, Friedland M, Brizendine L, Roberts E. Double-blind treatment of major depression with dehydroepiandrosterone. Am. J. Psychiatry, 1999, 156, 646-649.
184. Wood PL. The NMDA receptor complex: a long and winding road to therapeutics. Idrugs, 2005, 8, 229-235.
185. Zheng G, Sayama K, Okubo T, Juneja LR, Oguni I. Anti-obesity effects of three major components of green tea, catechins, caffeine and theanine, in mice. In Vivo, 2004, 18, 55-62.
186. Zwain IH, Yen SS. Neurosteroidogenesis in astrocytes, oligodendrocytes, and neurons of cerebral cortex of rat brain. Endocrinology, 1999, 140, 3843-3852.